scholarly journals Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Kazuya Sato ◽  
Nodoka Tsukada ◽  
Junki Inamura ◽  
Shigetsuna Komatsu ◽  
Keisuke Sato ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Therapeutic Option ◽  
Myeloid Sarcoma ◽  
Intermittent Treatment ◽  
Tumor Biopsy ◽  
Topical Tacrolimus ◽  
Reduced Dose ◽  
Tumor Lesion ◽  
History Of

Myeloid sarcoma (MS), which involves extramedullary lesions, is classified as a unique subtype of acute myeloid leukemia (AML). At present, no standard treatments for MS have been established. The patient was an 89-year-old man with myelodysplastic syndrome-excess blast-2 (MDS-EB-2) with a 2-year history of intermittent treatment with azacitidine (AZA) during a 4-year history of MDS. He developed painful cutaneous tumors 8 months after the second discontinuation of AZA. They were refractory for antibiotics and topical tacrolimus hydrate. A tumor biopsy was performed, and the histological findings of the tumor lesion showed a proliferation of tumor cells that were positive for myeloperoxidase and CD68 and negative for CD4 and CD123. The patient was diagnosed with MDS-associated MS. MDS-EB-2 quickly progressed to AML with the appearance of peripheral blood blasts and 25% bone marrow blasts. Monotherapy with reduced-dose AZA (37.5 mg/m2 for 7 days, every 4–6 weeks) was restarted, and the MS quickly disappeared. The patient’s MS was successfully treated with 16 cycles of AZA treatment over a 22-month period. There have been 10 reported cases in which MS was successfully treated with AZA. Among the 10 cases, the patient in the present case was the oldest. Treatment with reduced-dose AZA should be considered as a therapeutic option for MS in elderly patients with MDS, especially patients who are ineligible for intensive chemotherapy.

scholarly journals Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
M. Malagola ◽  
N. Polverelli ◽  
V. Cancelli ◽  
E. Morello ◽  
A. Turra ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Clinical Risk Factors ◽  
Decision Algorithm ◽  
Platelet Recovery ◽  
Clinical Risk ◽  
History Of ◽  
Acute Myeloid

We present a case of a patient with a three-month history of peripheral blood cytopenia without a confirmed diagnosis of myelodysplastic syndrome, who developed a favourable-risk acute myeloid leukemia (AML), according to the European Leukemia Net (ELN) criteria. The patient achieved a complete remission with incomplete platelet recovery (CRi) after induction. The patient achieved the morphological CR after the first consolidation and completed the first-line treatment with a syngeneic stem cell transplantation (SCT). A disease relapse occurred after one year of CR (blast cell count in the bone marrow 15%), and the patient was offered a haplo-SCT, which he refused due to personal reasons. In this paper, we discuss the interplay between clinical and biological risk factors in non-high-risk AML patients and speculate that some old clinical risk factors (e.g., age of the patient, achievement of CR after induction, and previous history of myelodysplastic syndrome) may still impact on the treatment decision algorithm of some of these patients.

Topical Tacrolimus in the Treatment of Erosive Pustular Dermatosis of the Scalp

2007 ◽  
Vol 11 (6) ◽  
pp. 222-225 ◽  
Author(s):  
Marta J. Cenkowski ◽  
Shane Silver
Keyword(s):  
Light Exposure ◽  
Therapeutic Option ◽  
Rare Condition ◽  
Initial Therapy ◽  
Topical Steroids ◽  
Topical Tacrolimus ◽  
History Of ◽  
Prevention Of Relapse

Background: Erosive pustular dermatosis of the scalp (EPDS) is a rare condition characterized by chronic, sterile, pustular erosions leading to scarring alopecia. Although the etiology is unknown, it appears to be associated with ultraviolet light exposure and trauma. Histologic findings include nonspecific atrophy of the epidermis and chronic inflammation. Case History: A 71-year-old female presented with a 1-year history of a boggy, erythematous, friable plaque on the vertex of her scalp. A diagnosis of EPDS was made based on presentation, negative cultures, and histologic findings. Initial therapy with intralesional and topical steroids and oral antibiotics resolved the inflamed plaques; however, steroid-induced atrophy became prominent after 5 months of use. The treatment was discontinued, resulting in recurrence of disease. Topical tacrolimus 0.1% ointment was initiated, which has been successfully controlling the lesions with reversal of skin atrophy and clinical evidence of hair growth. Conclusion: This is the fourth reported case of the successful treatment of EPDS with topical tacrolimus for the resolution of atrophy and the prevention of relapse of inflammation. Although its long-term use warrants close follow-up for side effects, tacrolimus may constitute a novel therapeutic option for the treatment of EPDS.

scholarly journals A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Takahiro Kumode ◽  
Ayano Fukui ◽  
Go Eguchi ◽  
Terufumi Yamaguchi ◽  
Yasuhiro Maeda
Keyword(s):  
Acute Myeloid Leukemia ◽  
Elderly Patients ◽  
Myelodysplastic Syndrome ◽  
Physical Condition ◽  
Myeloid Leukemia ◽  
Therapeutic Option ◽  
Tumor Burden ◽  
Secondary Leukemia ◽  
Secondary Acute Myeloid Leukemia ◽  
Acute Myeloid

Elderly patients with secondary acute myeloid leukemia (AML) following myelodysplastic syndrome (MDS) are often medically unfit for or resistant to chemotherapy, and their prognosis is dismal. In the present paper, we reported a case of secondary leukemia following MDS in an 80-year-old male patient who was deemed unfit for chemotherapy owing to his old age and poor physical condition. Despite a high tumor burden, treatment with AZA exerted a remarkable response, leading to an immediate cytoreduction in our case. Our results suggest that AZA can be an attractive therapeutic option for elderly MDS or AML patients, offering adequate efficacy and high tolerability.

scholarly journals Acute Myeloid Leukemia Presenting as Acute Bulbar Palsy

2014 ◽  
Vol 13 (4) ◽  
pp. 481-483
Author(s):  
Kiran Kumar Singal ◽  
Ajay Mittal ◽  
Rajni Aggarwal ◽  
Saurav Aggarwal ◽  
Rao Farman Khan ◽  
...  
Keyword(s):  
Brain Stem ◽  
Myeloid Leukemia ◽  
Medical Science ◽  
Granulocytic Sarcoma ◽  
Myeloid Sarcoma ◽  
History Of ◽  
The Central Nervous System ◽  
Immature Myeloid Cells ◽  
Laboratory Investigations ◽  
The Brain

Myeloid Sarcoma1 (also termed as chloroma, granulocytic sarcoma, extra medullary myeloid tumor) is a rare extra medullary tumor composed of immature myeloid cells (myeloblast)2. It is usually associated with leukemia or other myeloproliferative disorder. Myeloid Sarcoma in the central nervous system, around the brain stem is the commonest site of presentation and require high suspicion for diagnosis. We report a forty years male patient with history of dysphagia, dysphonia for last two months. MRI showed chloromas around the brain stem. Laboratory investigations revealed the presence of AML. This is a rare case of Myeloid Sarcoma around the brain stem in a patient of AML. DOI: http://dx.doi.org/10.3329/bjms.v13i4.16056 Bangladesh Journal of Medical Science Vol.13(4) 2014 p.481-483

scholarly journals Primary Myeloid Sarcoma of the Prostate: A Case Report and Literature Review

2018 ◽  
Vol 2018 ◽  
pp. 1-5
Author(s):  
Ryan Nguyen ◽  
Hamid Sayar
Keyword(s):  
Myeloid Leukemia ◽  
Bone Marrow Examination ◽  
Myeloid Sarcoma ◽  
Remission Induction ◽  
Prior History ◽  
Conventional Chemotherapy ◽  
Hematologic Disorders ◽  
History Of ◽  
One Year ◽  
Acute Myeloid

We report the case of a 73-year-old male with primary myeloid sarcoma (MS) of the prostate. He underwent remission-induction chemotherapy followed by conventional consolidation for acute myeloid leukemia (AML). One year after initial diagnosis, he was without evidence of AML, the longest reported period of time in the literature for a case of primary MS of the prostate. From 1985 to 2017, fifteen other cases of MS of the prostate have been reported and are reviewed here. Five cases occurred as primary MS, without evidence of AML on bone marrow examination or prior history of hematologic disorders, and progressed to AML within a range of three weeks to seven months. None of these cases were started on conventional chemotherapy for AML prior to progression. Due to its rarity, primary MS of the prostate is often diagnosed incidentally, but prompt AML-targeted treatment is crucial to delaying the progression to AML.

scholarly journals Sacral Myeloid Sarcoma Manifesting as Radiculopathy in a Pediatric Patient: An Unusual Form of Myeloid Leukemia Relapse

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Joana Ruivo Rodrigues ◽  
Manuel João Brito ◽  
Rui Pedro Faria Pais ◽  
Sílvia Carvalho
Keyword(s):  
Emergency Department ◽  
Bone Marrow ◽  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Pediatric Patient ◽  
Myeloid Leukemia ◽  
Granulocytic Sarcoma ◽  
Myeloid Sarcoma ◽  
Leukemia Relapse ◽  
Acute Myeloid

Myeloid sarcoma (MS), granulocytic sarcoma or chloroma, is defined as a localized extramedullary mass of blasts of granulocytic lineage with or without maturation, occurring outside the bone marrow. MS can be diagnosed concurrently with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The authors report a case of sacral MS occurring as a relapse of myeloid leukemia in a 5-year-old girl who was taken to the emergency department with radiculopathy symptoms.

scholarly journals Frequency of Hematologic and Solid Malignancies in the Family History of Patients with Myeloid Neoplasms

2022 ◽  
Author(s):  
Alaa Ali ◽  
Batool Yassin ◽  
Ali Almothaffar
Keyword(s):  
Acute Myeloid Leukemia ◽  
Family History ◽  
Myelodysplastic Syndrome ◽  
Aplastic Anemia ◽  
Myeloid Leukemia ◽  
Myeloid Neoplasms ◽  
Solid Malignancies ◽  
History Of ◽  
Acute Myeloid ◽  
Second Degree

Background: Studies demonstrated that there are several germline mutations that lead to a familial predisposition for acute myeloid leukemia and Myelodysplastic syndrome. According to the American Society of Clinical Oncology, the minimum cancer family history was defined as including first- and second-degree family history, type of primary cancer, and age at diagnosis. The current study aimed to estimate the frequency of positive family history for hematologic and solid malignancies in patients with Myeloid Neoplasms / Aplastic anemia. Patients and Methods: A cross-section study was carried out at the Center of Blood Diseases, Medical City Campus during the period from March-December 2020. A purposeful sample of all adult patients with Myeloid Neoplasms [Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia, and Aplastic Anemia] was included in the study. A data collection form was prepared, based on the Hereditary Hematopoietic Malignancies Screening form adopted by the University of Chicago, and modified by the researchers; The data were collected by direct interview with the patients. Patients with hematologic malignancy and one or more first-degree relatives, or ≥2 second-degree relatives, with hematologic malignancies and individuals with Myelodysplastic Syndrome or Acute Myeloid Leukemia and two first or second-degree relatives with a diagnosis of solid tumor malignancy, were considered potential carriers of such genetic predisposition. Results: A total of 153 patients were included; males were nearly equal to females with a male to female ratio of nearly 1:1. Acute Myeloid Leukemia was found in 57.5%, Aplastic Anemia was found in 19%, Chronic Myeloid Leukemia in 17% and only four patients (6.5%) were known cases of Myelodysplastic Syndrome. Nine patients (5.9%) reported a family history of hematological malignancies, 29 (19.0%) reported a family history of solid malignancies and only one patient reported a family history of both hematological and solid malignancies. Regarding the official medical reports of the patients, no patient had been interviewed properly about this crucial point. Conclusion: Positive family history for hematological and solid malignancies in Iraqi patients with myeloid neoplasms is prevalent. Our current approach to this critical issue in Iraq needs to be re-considered.

scholarly journals A Case of Myeloid Sarcoma in the Nasal Cavity Occurred in the Patient with Leukemic Transformation in Myelodysplastic Syndrome

2020 ◽  
Vol 63 (2) ◽  
pp. 81-84
Author(s):  
Dong Hoo Lee ◽  
Sung Yool Park ◽  
Ha Young Park ◽  
Seong Kook Park
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Nasal Cavity ◽  
Myeloid Leukemia ◽  
Rare Case ◽  
De Novo ◽  
Myeloid Sarcoma ◽  
Leukemic Transformation ◽  
Normal Architecture ◽  
Acute Myeloid

Myeloid sarcoma is characterized by the presence of myeloid blasts at an extramedullar site that disrupts the normal architecture of the organ. Many of these cases are associated with acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, or occur in de novo. It occurs most commonly in skin, lymph node, gastrointestinal tract, bone, soft tissue but, rarely in head and neck; especially in nasal cavity. Therefore, it is often misdiagnosed as a different disease: most commonly as lymphoma. Here we report a rare case of myeloid sarcoma in the nasal cavity that occurred in a patient with leukemic transformation with myelodysplastic syndrome, provided with literature review.

Sign in / Sign up

Export Citation Format

Share Document